Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 78

1.

Bronchiectasis and Chronic Airway Disease: It Is Not Just About Asthma and COPD.

Martinez-Garcia MA, Polverino E, Aksamit T.

Chest. 2018 Oct;154(4):737-739. doi: 10.1016/j.chest.2018.02.024. No abstract available.

PMID:
30290922
2.

The overlap between bronchiectasis and chronic airway diseases: state of the art and future directions.

Polverino E, Dimakou K, Hurst J, Martinez-Garcia MA, Miravitlles M, Paggiaro P, Shteinberg M, Aliberti S, Chalmers JD.

Eur Respir J. 2018 Sep 15;52(3). pii: 1800328. doi: 10.1183/13993003.00328-2018. Print 2018 Sep. Review.

PMID:
30049739
3.

Addition of hyaluronic acid improves tolerance to 7% hypertonic saline solution in bronchiectasis patients.

Máiz L, Girón RM, Prats E, Clemente MG, Polverino E, Caño S, Cordovilla R, Dorca J, Peñalver C, Baranda F, Martínez-García MA.

Ther Adv Respir Dis. 2018 Jan-Dec;12:1753466618787385. doi: 10.1177/1753466618787385.

4.

Impact of Hypertonic Saline Solutions on Sputum Expectoration and Their Safety Profile in Patients with Bronchiectasis: A Randomized Crossover Trial.

Herrero-Cortina B, Alcaraz V, Vilaró J, Torres A, Polverino E.

J Aerosol Med Pulm Drug Deliv. 2018 Oct;31(5):281-289. doi: 10.1089/jamp.2017.1443. Epub 2018 Jun 7.

PMID:
29878856
5.

Pneumonic and non-pneumonic exacerbations in bronchiectasis: Clinical and microbiological differences.

Polverino E, Rosales-Mayor E, Benegas M, Menendez R, Alcaraz-Serrano V, Ansotegui E, Montull B, Girón RM, Cisneros C, Vendrell M, Muñoz G, Marcos MA, Sanchez M, Torres A.

J Infect. 2018 Aug;77(2):99-106. doi: 10.1016/j.jinf.2018.04.006. Epub 2018 May 7.

PMID:
29746946
6.

The independent contribution of Pseudomonas aeruginosa infection to long-term clinical outcomes in bronchiectasis.

Araújo D, Shteinberg M, Aliberti S, Goeminne PC, Hill AT, Fardon TC, Obradovic D, Stone G, Trautmann M, Davis A, Dimakou K, Polverino E, De Soyza A, McDonnell MJ, Chalmers JD.

Eur Respir J. 2018 Jan 31;51(2). pii: 1701953. doi: 10.1183/13993003.01953-2017. Print 2018 Feb.

PMID:
29386336
7.

RESPIRE 2: a phase III placebo-controlled randomised trial of ciprofloxacin dry powder for inhalation in non-cystic fibrosis bronchiectasis.

Aksamit T, De Soyza A, Bandel TJ, Criollo M, Elborn JS, Operschall E, Polverino E, Roth K, Winthrop KL, Wilson R.

Eur Respir J. 2018 Jan 25;51(1). pii: 1702053. doi: 10.1183/13993003.02053-2017. Print 2018 Jan.

PMID:
29371384
8.

RESPIRE 1: a phase III placebo-controlled randomised trial of ciprofloxacin dry powder for inhalation in non-cystic fibrosis bronchiectasis.

De Soyza A, Aksamit T, Bandel TJ, Criollo M, Elborn JS, Operschall E, Polverino E, Roth K, Winthrop KL, Wilson R.

Eur Respir J. 2018 Jan 25;51(1). pii: 1702052. doi: 10.1183/13993003.02052-2017. Print 2018 Jan.

PMID:
29371383
9.

Severe community-acquired pneumonia: Characteristics and prognostic factors in ventilated and non-ventilated patients.

Ferrer M, Travierso C, Cilloniz C, Gabarrus A, Ranzani OT, Polverino E, Liapikou A, Blasi F, Torres A.

PLoS One. 2018 Jan 25;13(1):e0191721. doi: 10.1371/journal.pone.0191721. eCollection 2018.

10.

Characterization of the "Frequent Exacerbator Phenotype" in Bronchiectasis.

Chalmers JD, Aliberti S, Filonenko A, Shteinberg M, Goeminne PC, Hill AT, Fardon TC, Obradovic D, Gerlinger C, Sotgiu G, Operschall E, Rutherford RM, Dimakou K, Polverino E, De Soyza A, McDonnell MJ.

Am J Respir Crit Care Med. 2018 Jun 1;197(11):1410-1420. doi: 10.1164/rccm.201711-2202OC.

PMID:
29357265
11.

Cross-infection risk in patients with bronchiectasis: a position statement from the European Bronchiectasis Network (EMBARC), EMBARC/ELF patient advisory group and European Reference Network (ERN-Lung) Bronchiectasis Network.

Chalmers JD, Ringshausen FC, Harris B, Elborn JS, Posthumus A, Haworth CS, Pilkington N, Polverino E, Ruddy T, Aliberti S, Goeminne PC, Winstanley C, De Soyza A.

Eur Respir J. 2018 Jan 11;51(1). pii: 1701937. doi: 10.1183/13993003.01937-2017. Print 2018 Jan. No abstract available.

PMID:
29326319
12.

Macrolides, mucoactive drugs and adherence for the management of bronchiectasis.

Chalmers JD, Polverino E; European Respiratory Society Bronchiectasis Guidelines Task Force.

Eur Respir J. 2018 Jan 4;51(1). pii: 1702033. doi: 10.1183/13993003.02033-2017. Print 2018 Jan. No abstract available.

PMID:
29301926
13.

The BRICS (Bronchiectasis Radiologically Indexed CT Score): A Multicenter Study Score for Use in Idiopathic and Postinfective Bronchiectasis.

Bedi P, Chalmers JD, Goeminne PC, Mai C, Saravanamuthu P, Velu PP, Cartlidge MK, Loebinger MR, Jacob J, Kamal F, Schembri N, Aliberti S, Hill U, Harrison M, Johnson C, Screaton N, Haworth C, Polverino E, Rosales E, Torres A, Benegas MN, Rossi AG, Patel D, Hill AT.

Chest. 2018 May;153(5):1177-1186. doi: 10.1016/j.chest.2017.11.033. Epub 2017 Dec 13.

PMID:
29247616
14.

Standardised classification of the aetiology of bronchiectasis using an objective algorithm.

Araújo D, Shteinberg M, Aliberti S, Goeminne PC, Hill AT, Fardon T, Obradovic D, Dimakou K, Polverino E, De Soyza A, McDonnell MJ, Chalmers JD.

Eur Respir J. 2017 Dec 14;50(6). pii: 1701289. doi: 10.1183/13993003.01289-2017. Print 2017 Dec. No abstract available.

PMID:
29242262
15.

Spanish Guidelines on the Evaluation and Diagnosis of Bronchiectasis in Adults.

Martínez-García MÁ, Máiz L, Olveira C, Girón RM, de la Rosa D, Blanco M, Cantón R, Vendrell M, Polverino E, de Gracia J, Prados C.

Arch Bronconeumol. 2018 Feb;54(2):79-87. doi: 10.1016/j.arbres.2017.07.015. Epub 2017 Nov 9. English, Spanish.

16.

Spanish Guidelines on Treatment of Bronchiectasis in Adults.

Martínez-García MÁ, Máiz L, Olveira C, Girón RM, de la Rosa D, Blanco M, Cantón R, Vendrell M, Polverino E, de Gracia J, Prados C.

Arch Bronconeumol. 2018 Feb;54(2):88-98. doi: 10.1016/j.arbres.2017.07.016. Epub 2017 Nov 9. English, Spanish.

17.

Pulmonary disease by non-tuberculous mycobacteria - clinical management, unmet needs and future perspectives.

Larsson LO, Polverino E, Hoefsloot W, Codecasa LR, Diel R, Jenkins SG, Loebinger MR.

Expert Rev Respir Med. 2017 Dec;11(12):977-989. doi: 10.1080/17476348.2017.1386563. Epub 2017 Oct 10. Review.

PMID:
28967797
18.

Risk factors for multidrug-resistant pathogens in bronchiectasis exacerbations.

Menéndez R, Méndez R, Polverino E, Rosales-Mayor E, Amara-Elori I, Reyes S, Sahuquillo-Arce JM, Fernández-Barat L, Alcaraz V, Torres A.

BMC Infect Dis. 2017 Sep 30;17(1):659. doi: 10.1186/s12879-017-2754-5.

19.

Factors associated with hospitalization in bronchiectasis exacerbations: a one-year follow-up study.

Menéndez R, Méndez R, Polverino E, Rosales-Mayor E, Amara-Elori I, Reyes S, Posadas T, Fernández-Barat L, Torres A.

Respir Res. 2017 Sep 30;18(1):176. doi: 10.1186/s12931-017-0659-x.

20.

Acute exacerbations of COPD: risk factors for failure and relapse.

Mantero M, Rogliani P, Di Pasquale M, Polverino E, Crisafulli E, Guerrero M, Gramegna A, Cazzola M, Blasi F.

Int J Chron Obstruct Pulmon Dis. 2017 Sep 8;12:2687-2693. doi: 10.2147/COPD.S145253. eCollection 2017. Review.

21.

Patient participation in ERS guidelines and research projects: the EMBARC experience.

Chalmers JD, Timothy A, Polverino E, Almagro M, Ruddy T, Powell P, Boyd J.

Breathe (Sheff). 2017 Sep;13(3):194-207. doi: 10.1183/20734735.009517. Review.

22.

The European Multicentre Bronchiectasis Audit and Research Collaboration (EMBARC): experiences from a successful ERS Clinical Research Collaboration.

Chalmers JD, Crichton M, Goeminne PC, Loebinger MR, Haworth C, Almagro M, Vendrell M, De Soyza A, Dhar R, Morgan L, Blasi F, Aliberti S, Boyd J, Polverino E.

Breathe (Sheff). 2017 Sep;13(3):180-192. doi: 10.1183/20734735.005117. Review.

23.

European Respiratory Society guidelines for the management of adult bronchiectasis.

Polverino E, Goeminne PC, McDonnell MJ, Aliberti S, Marshall SE, Loebinger MR, Murris M, Cantón R, Torres A, Dimakou K, De Soyza A, Hill AT, Haworth CS, Vendrell M, Ringshausen FC, Subotic D, Wilson R, Vilaró J, Stallberg B, Welte T, Rohde G, Blasi F, Elborn S, Almagro M, Timothy A, Ruddy T, Tonia T, Rigau D, Chalmers JD.

Eur Respir J. 2017 Sep 9;50(3). pii: 1700629. doi: 10.1183/13993003.00629-2017. Print 2017 Sep.

PMID:
28889110
24.

Pulmonary exacerbation in adults with bronchiectasis: a consensus definition for clinical research.

Hill AT, Haworth CS, Aliberti S, Barker A, Blasi F, Boersma W, Chalmers JD, De Soyza A, Dimakou K, Elborn JS, Feldman C, Flume P, Goeminne PC, Loebinger MR, Menendez R, Morgan L, Murris M, Polverino E, Quittner A, Ringshausen FC, Tino G, Torres A, Vendrell M, Welte T, Wilson R, Wong C, O'Donnell A, Aksamit T; EMBARC/BRR definitions working group.

Eur Respir J. 2017 Jun 8;49(6). pii: 1700051. doi: 10.1183/13993003.00051-2017. Print 2017 Jun.

PMID:
28596426
25.

The RESPIRE trials: Two phase III, randomized, multicentre, placebo-controlled trials of Ciprofloxacin Dry Powder for Inhalation (Ciprofloxacin DPI) in non-cystic fibrosis bronchiectasis.

Aksamit T, Bandel TJ, Criollo M, De Soyza A, Elborn JS, Operschall E, Polverino E, Roth K, Winthrop KL, Wilson R.

Contemp Clin Trials. 2017 Jul;58:78-85. doi: 10.1016/j.cct.2017.05.007. Epub 2017 May 8.

26.

The Role of Neutrophil Elastase Inhibitors in Lung Diseases.

Polverino E, Rosales-Mayor E, Dale GE, Dembowsky K, Torres A.

Chest. 2017 Aug;152(2):249-262. doi: 10.1016/j.chest.2017.03.056. Epub 2017 Apr 23. Review.

PMID:
28442313
27.

Sex bias in diagnostic delay in bronchiectasis: An analysis of the Spanish Historical Registry of Bronchiectasis.

Girón RM, de Gracia Roldán J, Olveira C, Vendrell M, Martínez-García MÁ, de la Rosa D, Máiz L, Ancochea J, Vázquez L, Borderías L, Polverino E, Martínez-Moragón E, Rajas O, Soriano JB.

Chron Respir Dis. 2017 Nov;14(4):360-369. doi: 10.1177/1479972317702139. Epub 2017 Apr 10.

28.

Comparison of two prognostic scores (BSI and FACED) in a Spanish cohort of adult patients with bronchiectasis and improvement of the FACED predictive capacity for exacerbations.

Rosales-Mayor E, Polverino E, Raguer L, Alcaraz V, Gabarrus A, Ranzani O, Menendez R, Torres A.

PLoS One. 2017 Apr 6;12(4):e0175171. doi: 10.1371/journal.pone.0175171. eCollection 2017.

29.

Antibiotic therapy prior to hospital admission is associated with reduced septic shock and need for mechanical ventilation in patients with community-acquired pneumonia.

Amaro R, Sellarés J, Polverino E, Cillóniz C, Ferrer M, Fernández-Barat L, Mensa J, Niederman MS, Torres A.

J Infect. 2017 May;74(5):442-449. doi: 10.1016/j.jinf.2017.01.009. Epub 2017 Jan 24.

PMID:
28130142
30.

Etiology of Bronchiectasis in a Cohort of 2047 Patients. An Analysis of the Spanish Historical Bronchiectasis Registry.

Olveira C, Padilla A, Martínez-García MÁ, de la Rosa D, Girón RM, Vendrell M, Máiz L, Borderías L, Polverino E, Martínez-Moragón E, Rajas O, Casas F, Cordovilla R, de Gracia J.

Arch Bronconeumol. 2017 Jul;53(7):366-374. doi: 10.1016/j.arbres.2016.12.003. Epub 2017 Jan 21. English, Spanish.

31.

Invasive Disease vs Urinary Antigen-Confirmed Pneumococcal Community-Acquired Pneumonia.

Ceccato A, Torres A, Cilloniz C, Amaro R, Gabarrus A, Polverino E, Prina E, Garcia-Vidal C, Muñoz-Conejero E, Mendez C, Cifuentes I, Puig de la Bella Casa J, Menendez R, Niederman MS.

Chest. 2017 Jun;151(6):1311-1319. doi: 10.1016/j.chest.2017.01.005. Epub 2017 Jan 16.

PMID:
28093269
32.

The best of respiratory infections from the 2015 European Respiratory Society International Congress.

Polverino E, Bothamley GH, Goletti D, Heyckendorf J, Sotgiu G, Aliberti S.

ERJ Open Res. 2016 Jul 11;2(3). pii: 00049-2016. eCollection 2016 Jul.

33.

The EMBARC European Bronchiectasis Registry: protocol for an international observational study.

Chalmers JD, Aliberti S, Polverino E, Vendrell M, Crichton M, Loebinger M, Dimakou K, Clifton I, van der Eerden M, Rohde G, Murris-Espin M, Masefield S, Gerada E, Shteinberg M, Ringshausen F, Haworth C, Boersma W, Rademacher J, Hill AT, Aksamit T, O'Donnell A, Morgan L, Milenkovic B, Tramma L, Neves J, Menendez R, Paggiaro P, Botnaru V, Skrgat S, Wilson R, Goeminne P, De Soyza A, Welte T, Torres A, Elborn JS, Blasi F.

ERJ Open Res. 2016 Jan 20;2(1). pii: 00081-2015. eCollection 2016 Jan.

34.

The Importance of Phenotyping Bronchiectasis.

Battaglia S, Torres A, Polverino E.

Respiration. 2016;92(3):134-5. doi: 10.1159/000448557. Epub 2016 Sep 3. No abstract available.

35.

Challenges in managing Pseudomonas aeruginosa in non-cystic fibrosis bronchiectasis.

Wilson R, Aksamit T, Aliberti S, De Soyza A, Elborn JS, Goeminne P, Hill AT, Menendez R, Polverino E.

Respir Med. 2016 Aug;117:179-89. doi: 10.1016/j.rmed.2016.06.007. Epub 2016 Jun 7. Review.

36.

Research priorities in bronchiectasis: a consensus statement from the EMBARC Clinical Research Collaboration.

Aliberti S, Masefield S, Polverino E, De Soyza A, Loebinger MR, Menendez R, Ringshausen FC, Vendrell M, Powell P, Chalmers JD; EMBARC Study Group.

Eur Respir J. 2016 Sep;48(3):632-47. doi: 10.1183/13993003.01888-2015. Epub 2016 Jun 10.

37.

Predictive and prognostic factors in patients with blood-culture-positive community-acquired pneumococcal pneumonia.

Amaro R, Liapikou A, Cilloniz C, Gabarrus A, Marco F, Sellares J, Polverino E, Garau J, Ferrer M, Musher DM, Torres A.

Eur Respir J. 2016 Sep;48(3):797-807. doi: 10.1183/13993003.00039-2016. Epub 2016 May 12.

38.

Validation of a Spanish version of the Leicester Cough Questionnaire in non-cystic fibrosis bronchiectasis.

Muñoz G, Buxó M, de Gracia J, Olveira C, Martinez-Garcia MA, Giron R, Polverino E, Alvarez A, Birring SS, Vendrell M.

Chron Respir Dis. 2016 May;13(2):128-36. doi: 10.1177/1479972316632005. Epub 2016 Feb 22.

39.

Short-term effects of three slow expiratory airway clearance techniques in patients with bronchiectasis: a randomised crossover trial.

Herrero-Cortina B, Vilaró J, Martí D, Torres A, San Miguel-Pagola M, Alcaraz V, Polverino E.

Physiotherapy. 2016 Dec;102(4):357-364. doi: 10.1016/j.physio.2015.07.005. Epub 2015 Dec 1.

PMID:
26712530
40.

Community acquired pneumonia in asthma: Not a threatening combination.

Polverino E, Torres A, Terraneo S.

Respir Med. 2016 Mar;112:136. doi: 10.1016/j.rmed.2015.11.013. Epub 2015 Dec 8. No abstract available.

41.

Etiology of Non-Cystic Fibrosis Bronchiectasis in Adults and Its Correlation to Disease Severity.

Lonni S, Chalmers JD, Goeminne PC, McDonnell MJ, Dimakou K, De Soyza A, Polverino E, Van de Kerkhove C, Rutherford R, Davison J, Rosales E, Pesci A, Restrepo MI, Torres A, Aliberti S.

Ann Am Thorac Soc. 2015 Dec;12(12):1764-70. doi: 10.1513/AnnalsATS.201507-472OC.

42.

Microbiology and outcomes of community acquired pneumonia in non cystic-fibrosis bronchiectasis patients.

Polverino E, Cilloniz C, Menendez R, Gabarrus A, Rosales-Mayor E, Alcaraz V, Terraneo S, Puig de la Bella Casa J, Mensa J, Ferrer M, Torres A.

J Infect. 2015 Jul;71(1):28-36. doi: 10.1016/j.jinf.2015.03.009. Epub 2015 Apr 14.

PMID:
25882347
43.

Effect of corticosteroids on treatment failure among hospitalized patients with severe community-acquired pneumonia and high inflammatory response: a randomized clinical trial.

Torres A, Sibila O, Ferrer M, Polverino E, Menendez R, Mensa J, Gabarrús A, Sellarés J, Restrepo MI, Anzueto A, Niederman MS, Agustí C.

JAMA. 2015 Feb 17;313(7):677-86. doi: 10.1001/jama.2015.88.

44.

Bacteraemia and antibiotic-resistant pathogens in community acquired pneumonia: risk and prognosis.

Torres A, Cillóniz C, Ferrer M, Gabarrús A, Polverino E, Villegas S, Marco F, Mensa J, Menéndez R, Niederman M.

Eur Respir J. 2015 May;45(5):1353-63. doi: 10.1183/09031936.00152514. Epub 2015 Jan 22.

45.

Risk factors associated with potentially antibiotic-resistant pathogens in community-acquired pneumonia.

Prina E, Ranzani OT, Polverino E, Cillóniz C, Ferrer M, Fernandez L, Puig de la Bellacasa J, Menéndez R, Mensa J, Torres A.

Ann Am Thorac Soc. 2015 Feb;12(2):153-60. doi: 10.1513/AnnalsATS.201407-305OC.

PMID:
25521229
46.

Severity and outcomes of community acquired pneumonia in asthmatic patients.

Terraneo S, Polverino E, Cilloniz C, Amaro R, Vennera Mdel C, Gabarrus A, Montull B, Moreno E, Menendez R, Centanni S, Torres A.

Respir Med. 2014 Nov;108(11):1713-22. doi: 10.1016/j.rmed.2014.09.001. Epub 2014 Sep 16.

47.

Inhaled corticosteroids and systemic inflammatory response in community-acquired pneumonia: a prospective clinical study.

Ferrer M, Torres A, Martínez R, Ramírez P, Polverino E, Montull B, Sialer S, Niederman MS, Agusti A, Menéndez R.

Respirology. 2014 Aug;19(6):929-35. doi: 10.1111/resp.12324. Epub 2014 Jun 9.

48.

Author's response to 'CAP and HCAP are different? An unresolved question'.

Polverino E, Torres A; HCAP study group.

Thorax. 2014 Jul;69(7):677-8. doi: 10.1136/thoraxjnl-2014-205210. Epub 2014 Mar 25. No abstract available.

49.

Phenotyping community-acquired pneumonia according to the presence of acute respiratory failure and severe sepsis.

Aliberti S, Brambilla AM, Chalmers JD, Cilloniz C, Ramirez J, Bignamini A, Prina E, Polverino E, Tarsia P, Pesci A, Torres A, Blasi F, Cosentini R.

Respir Res. 2014 Mar 4;15:27. doi: 10.1186/1465-9921-15-27.

50.

Community-acquired lung respiratory infections in HIV-infected patients: microbial aetiology and outcome.

Cilloniz C, Torres A, Polverino E, Gabarrus A, Amaro R, Moreno E, Villegas S, Ortega M, Mensa J, Marcos MA, Moreno A, Miro JM.

Eur Respir J. 2014 Jun;43(6):1698-708. doi: 10.1183/09031936.00155813. Epub 2014 Feb 13.

Supplemental Content

Loading ...
Support Center